^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
OriCAR-017
i
Other names: OriCAR-017, GPRC5D CAR T, Ori-CAR017, OriCAR017, OriCAR 017
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Oricell
Drug class:
GPRC5D-targeted CAR-T immunotherapy
Related drugs:
6ms
OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM (clinicaltrials.gov)
P1/2, N=83, Recruiting, OriCell Therapeutics Co., Ltd. | Enrolling by invitation --> Recruiting
Enrollment status
|
OriCAR-017
6ms
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study (clinicaltrials.gov)
P1, N=81, Recruiting, OriCell Therapeutics Co., Ltd. | Not yet recruiting --> Recruiting | Trial completion date: Apr 2026 --> Apr 2028 | Trial primary completion date: Dec 2025 --> Dec 2026
Enrollment open • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
OriCAR-017
8ms
OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM (clinicaltrials.gov)
P1/2, N=83, Enrolling by invitation, OriCell Therapeutics Co., Ltd. | Recruiting --> Enrolling by invitation
Enrollment status
|
OriCAR-017
9ms
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM (clinicaltrials.gov)
P1, N=81, Not yet recruiting, OriCell Therapeutics Co., Ltd.
New P1 trial
|
OriCAR-017
11ms
OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM (clinicaltrials.gov)
P1/2, N=83, Recruiting, OriCell Therapeutics Co., Ltd.
New P1/2 trial
|
OriCAR-017
almost2years
GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. (PubMed, Lancet Haematol)
The results of this study suggest that GPRC5D is an active target for immunotherapy in multiple myeloma. GPRC5D-targeted CAR T-cell therapy is a promising treatment modality for patients with relapsed or refractory multiple myeloma and deserves further testing.
P1 data • Journal • CAR T-Cell Therapy • IO biomarker
|
GPRC5D (G Protein-Coupled Receptor Class C Group 5 Member D)
|
OriCAR-017
2years
POLARIS: A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma (clinicaltrials.gov)
P1, N=15, Active, not recruiting, Zhejiang University | Recruiting --> Active, not recruiting
Enrollment closed • CAR T-Cell Therapy
|
GPRC5D (G Protein-Coupled Receptor Class C Group 5 Member D)
|
OriCAR-017
Share via
